Evidence map›Paper›PMID 40017972›Full record

ArticleBMJ public health2025

Challenges with achieving and maintaining oral cholera vaccine coverage: insights from serial cross-sectional representative surveys in a cholera-endemic community in the Democratic Republic of the Congo.

Aybüke Koyuncu, Patrick Musole Bugeme, Juan Dent, Chloe Hutchins, Hanmeng Xu, Karin Gallandat, Oliver Cumming, Joseph Matundanya, Aimé Cikomola, Delphin Rukakiza and 9 more

Abstract read
In one paragraph

Article in BMJ public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Community transmission of mpox clade Ib not driven through sexual exposures, Uvira, eastern Democratic Republic of the Congo, June to October 2024.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Aybüke KoyuncuDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Patrick Musole BugemeDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Juan DentDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Chloe HutchinsDepartment of Disease Control, London School of Hygiene and Tropical Medicine, London, UK.
Hanmeng XuDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Karin GallandatDepartment of Disease Control, London School of Hygiene and Tropical Medicine, London, UK.ORCID 0000-0001-6412-1483
Oliver CummingDepartment of Disease Control, London School of Hygiene and Tropical Medicine, London, UK.
Joseph MatundanyaProgramme Elargi de Vaccination, Ministère de la Santé Publique, Hygiène et Prévention, Bukavu, Congo (the Democratic Republic of the).
Aimé CikomolaProgramme Elargi de Vaccination, Ministère de la Santé Publique, Hygiène et Prévention, Bukavu, Congo (the Democratic Republic of the).
Delphin RukakizaProgramme Elargi de Vaccination, Ministère de la Santé Publique, Hygiène et Prévention, Bukavu, Congo (the Democratic Republic of the).
Merveille NkomboWorld Health Organization, Kinshasa, Congo (the Democratic Republic of the).
Jaime Saidi MufitiniZone de Santé d'Uvira, Ministère de la Santé Publique, Hygiène et Prévention, Uvira, South Kivu, Congo (the Democratic Republic of the).
Baron Bashige RumedekaDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Laurent AkilimaliProgramme National d'Elimination du Choléra et de Lutte Contre les autres Maladies Diarrhéiques (PNECHOL-MD), Ministère de la Santé Publique, Hygiène et Prévention, Kinshasa, Congo (the Democratic Republic of the).
Elizabeth C LeeDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Placide Okitayemba WeloProgramme National d'Elimination du Choléra et de Lutte Contre les autres Maladies Diarrhéiques (PNECHOL-MD), Ministère de la Santé Publique, Hygiène et Prévention, Kinshasa, Congo (the Democratic Republic of the).
Jackie KneeDepartment of Disease Control, London School of Hygiene and Tropical Medicine, London, UK.ORCID 0000-0002-0834-8488
Andrew S Azman *Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Espoir Bwenge Malembaka *Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.ORCID 0000-0001-9306-0253

Funding

Wellcome TrustWorld Health Organization 001
6 · The paper itself

Abstract

Background: We conducted three serial cross-sectional representative surveys after a mass cholera vaccination campaign in Uvira, Democratic Republic of the Congo to (1) estimate the vaccination coverage and explore heterogeneity by geographic and demographic factors; (2) examine barriers and facilitators of vaccine uptake and (3) describe the changes in coverage over time and predict future coverage. Methods: We collected data on sociodemographics, self-reported vaccination status, population movement and knowledge, attitudes and behaviours related to killed oral cholera vaccines (kOCVs) in August 2021, April 2022 and April 2023, approximately 11, 19 and 30 months postvaccination. We compared the characteristics of participants by vaccination status and explored the potential role of population movement as a cause for low coverage. We used an exponential decay model to predict the proportion of the population vaccinated with ≥1 dose of kOCV over time based on age-specific coverage. Results: We enrolled 8735 participants from 1433 households across all surveys. Coverage in survey 1 (August 2021) was 55% for ≥1 dose of kOCV (95% CI 51 to 60) and 23% for ≥2 doses (95% CI 20 to 27). Vaccine refusal was associated with a lack of confidence in the vaccine's safety, and 29% of unvaccinated adults reported it was unlikely they would accept kOCVs if an additional mass vaccination campaign was conducted in their area. Coverage of ≥1 one dose of kOCV declined on average by 18% per year (95% credible interval 14 to 23) and was 39% (95% CI 36 to 43) by survey 3 (approx. 30 months after second dose campaign). Conclusions: Our findings suggest that in settings like Uvira, efforts to strengthen vaccine confidence are needed to achieve higher campaign coverage, and vaccine coverage dilution may be reduced by more frequent and coordinated geographic vaccination efforts.

Indexed as

Disease OutbreaksDisease Transmission, InfectiousPreventive MedicinePrimary PreventionVaccination

Identifiers

PMID40017972
PMCPMC11812865

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.